Extended half-life drugs and libraries thereof, and methods of production and use

A nucleic acid pairing method for protein drugs forms a drug unit and half-life extension unit complex, addressing the limitations of existing half-life extension methods by providing stable, long-acting protein drugs with improved pharmacokinetics.

JP7588427B2Active Publication Date: 2024-11-22ASSEMBLY MEDICINE LLC
View PDF 1 Cites 0 Cited by

Patent Information

Application Number
JP2022526044
Authority / Receiving Office
JP · JP
Patent Type
Patents
Current Assignee / Owner
Priority Date
2019-10-29
Filing Date
2020-10-26
Publication Date
2024-11-22
Estimated Expiration
2040-10-26

AI Technical Summary

Technical Problem

Existing methods for extending the half-life of protein-based drugs, such as PEG modification and Fc or HSA fusion proteins, face challenges including immunogenicity, loss of biological activity, and limited effectiveness, particularly for naturally occurring proteins or polypeptides.

Method used

A modular and flexible method involving nucleic acid pairing to create a drug unit and half-life extension unit complex, allowing for rapid assembly of drugs with extended half-lives through complementary base pairing structures, utilizing FcRn-targeting units like HSA-binding proteins or nucleic acid aptamers.

Benefits of technology

The method enables drugs with significantly extended half-lives, stability, and reduced degradation, achieving cyclical utilization and improved pharmacokinetic properties without introducing new epitopes, suitable for various protein drugs.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 0007588427000009
    Figure 0007588427000009
  • Figure 0007588427000010
    Figure 0007588427000010
  • Figure 0007588427000011
    Figure 0007588427000011
Patent Text Reader

Abstract

The present invention provides half-life extended drugs and libraries thereof, as well as methods for producing and using them. Specifically, the present invention provides a drug library comprising (a) a drug unit and (b) n half-life extending units, wherein the drug unit comprises a drug element portion and a first nucleic acid element portion linked to the drug element portion, the half-life extending unit comprises a half-life extending element portion and a second nucleic acid element portion linked to the half-life extending element portion, and the first nucleic acid element portion of one drug unit monomer forms a complementary base pairing structure with the second nucleic acid element portion of at least one half-life extending unit to form a "drug unit-half-life extending unit" complex, wherein n is a positive integer ≧1.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The present invention relates to the field of biotechnological drugs, specifically to drugs with extended half-lives and libraries thereof, as well as methods of production and use. [Background technology]

[0002] For proteins or protein-based drugs, extending their half-life is advantageous for improving therapeutic efficacy and reducing drug usage. To extend the half-life of protein or polypeptide drugs, existing methods include making them into Fc-fusion proteins, HSA-fusion proteins, making Fc-protein / polypeptide complexes, HSA-protein / polypeptide complexes by chemical coupling, and changing the HSA in the fusion proteins or complexes into proteins or polypeptides (e.g., anti-HSA antibodies), small molecules, nucleic acids (e.g., aptamers), etc. that can bind to HSA, as well as chemical modification methods such as PEG, glycosylation, and sialic acid.

[0003] PEG modification is the main method for improving the half-life of protein or polypeptide drugs by chemical modification, the advantages of which are that PEG has strong biological adaptability and increases the solubility and stability of drugs, and the disadvantages are that PEG modification significantly affects the activity of active proteins such as biological enzymes, large molecular weight PEG is immunogenic, and the low uniformity of PEG molecules makes it difficult to control the quality of PEGylated drugs. In addition, the improvement of the half-life of proteins or polypeptides by chemical modification methods such as PEG depends on the increase in molecular weight, so there is a limit to the effect of improving the half-life.

[0004] Fc or HSA fusion proteins can extend half-life, but the method of extending half-life by Fc or HSA fusion proteins creates a new epitope at the fusion site of the protein or polypeptide of interest and the given Fc / HSA. In addition, Fc can only be fused to the C-terminus, and HSA can only be fused to the N-terminus or C-terminus of the protein or polypeptide of interest. In addition, the method is not suitable for naturally occurring proteins or polypeptides.

[0005] Therefore, there is a strong need in this field to develop a simple, flexible, efficient and modular linking means for specifically hetero-coupling protein drugs with half-life extenders (referring to HSA, HSA binding modules, etc.) so as to extend the half-life and improve the pharmacokinetic properties of protein drugs. Summary of the Invention [Problem to be solved by the invention]

[0006] It is an object of the present invention to provide a simple, flexible, efficient and modular method for specifically hetero-coupling protein drugs with half-life extenders and the coupled drugs produced thereby.

[0007] Another object of the present invention is to provide a low-cost modular FcRn targeting unit and a module library composed of the modular FcRn targeting unit, wherein the FcRn targeting unit is a half-life enhancing module that can flexibly link to a protein drug to significantly extend the half-life of the protein drug. [Means for solving the problem]

[0008] In a first aspect of the present invention, there is provided a drug library comprising: (a) a drug unit; and (b) n half-life extension units; wherein the drug unit comprises a drug element portion and a first nucleic acid element portion linked to the drug element portion; the half-life extension unit comprises a half-life extension element portion and a second nucleic acid element portion linked to the half-life element portion; and the first nucleic acid element portion of one of the drug units and the second nucleic acid element portion of at least one half-life extension unit form a complementary base pairing structure to form a "drug unit-half-life extension unit" complex; Here, n is provided as a positive integer ≧1.

[0009] In another preferred embodiment, the Drug unit and the half-life extending unit can be linked directly or indirectly through complementary bases. In another preferred embodiment, the "complementary base" includes a direct complementary base and / or an indirect complementary base.

[0010] In another preferred embodiment, the "directly complementary bases" include directly complementary bases between the first nucleic acid element portion and the second nucleic acid element portion. In another preferred embodiment, the "indirect complementary base" includes a triple or more pairing structure in which the first nucleic acid element portion and the second nucleic acid element portion form complementary bases via a single-stranded complementary sequence of one or more (e.g., 2, 3, 4, 5, 6) auxiliary complementary nucleic acid molecules (i.e., nucleic acid F).

[0011] In another preferred embodiment, the complementary nucleic acid molecule is in single-stranded form. In another preferred embodiment, the auxiliary complementary nucleic acid molecule is selected from the group consisting of an independent nucleic acid molecule, a second nucleic acid element portion of another half-life extension unit, a first nucleic acid element portion of another drug unit, or a combination thereof. In another preferred embodiment, the auxiliary complementary nucleic acid molecule is a nucleic acid that is not coupled to a protein drug.

[0012] In another preferred embodiment, the auxiliary complementary nucleic acid molecule is a first nucleic acid element portion of another distinct drug unit and / or a second nucleic acid element portion of another distinct half-life extension unit. In another preferred embodiment, the first nucleic acid element portion, the second nucleic acid element portion and / or the complementary auxiliary nucleic acid molecule are L-nucleic acids or nucleic acids modified by a modifying group.

[0013] In another preferred embodiment, the first nucleic acid element is not linked to the N-terminus (amino terminus) of the Drug unit moiety and / or is not linked to the C-terminus (carboxy terminus) of the Drug unit moiety. In another preferred embodiment, the first nucleic acid element is linked to a non-terminal amino acid residue portion of the Drug unit moiety.

[0014] In another preferred embodiment, the second nucleic acid element is not linked to the N-terminus (amino terminus) of the half-life extension element portion and / or is not linked to the C-terminus (carboxy terminus) of the half-life extension element portion. In another preferred embodiment, the second nucleic acid element is linked to a non-terminal amino acid residue portion of the half-life extension element portion.

[0015] In another preferred embodiment, the half-life extension element portion in the half-life extension unit is not Fc or a fragment thereof or a modified Fc or a fragment thereof (e.g., glycosylated Fc, NH2-modified Fc). In another preferred embodiment, the half-life extending element moiety in the half-life extending unit is not PEG (polyethylene glycol).

[0016] In another preferred embodiment, the "drug unit-half-life extension unit" conjugate has one type of half-life extension unit. In another preferred embodiment, the "drug unit-half-life extension unit" conjugate has two or more different types of half-life extension units. In another preferred embodiment, the "drug unit-half-life extending unit" conjugate has a molar ratio of the half-life extending unit to the drug unit (A / D) of 0.5-10, preferably 1-8, more preferably 2-5.

[0017] In another preferred embodiment, the "drug unit-half-life extending unit" conjugate has one type of drug unit. In another preferred embodiment, the "drug unit-half-life extension unit" conjugate has two or more different drug units. In another preferred embodiment, the "drug unit-half-life extending unit" conjugate has a molar ratio of the half-life extending unit to the drug unit (A / D) of 0.5-10, preferably 1-8, more preferably 2-5.

[0018] In another preferred embodiment, the drug element portion is a protein drug. In another preferred embodiment, the drug element portion is a polypeptide drug. In another preferred embodiment, the drug element portion is a fusion protein drug.

[0019] In another preferred embodiment, the “drug unit-half-life extending unit” conjugate has a structure represented by Formula I: [ka] (however, T0 is the drug element portion. L0 is for connecting T0 and A0, and is a nucleic acid linker containing a pairing structure based on complementary bases of the first nucleic acid element portion and the second nucleic acid element portion. A0 is an FcRn binding element, or a binding element that binds to an FcRn binding protein (eg, serum albumin). n is a positive integer ≧1.

[0020] In another preferred embodiment, the Drug Unit has the structure of Formula II: [ka] The half-life extending unit has a structure represented by Formula III. [ka] (In the formula, T is the drug element moiety. A is a half-life extending element moiety. X1 and X2 are either independent or overlapping peptides. L1 and L2 each independently represent a linker molecule. Y1, Y2, and Z1, Z2 are each independently null or overlapping nucleic acids. W1 and W2 each independently represent an L-nucleic acid, a peptide nucleic acid, a locked nucleic acid, a thio-modified nucleic acid, a 2'-fluoro-modified nucleic acid, 5-Hydroxymethylcytosine Nucleic Acid or a combination thereof. "-" is a conjugated bond. Here, the nucleic acid W1 of the drug unit has at least one complementary pairing region, and the nucleic acid W2 of the half-life extension element has at least one complementary pairing region, and the two are partially or completely complementary.

[0021] In another preferred embodiment, the drug element portion is selected from the group consisting of an antibody, a receptor, a ligand that activates or inhibits a protein, a bioactive enzyme, a nucleic acid drug, a small molecule drug, or a combination thereof.

[0022] In another preferred embodiment, the half-life extension element portion is selected from the group consisting of natural albumin, recombinant albumin, anti-albumin antibodies (including nanobodies, single-chain antibodies, Fabs, and monoclonal antibodies), nucleic acid aptamers that specifically bind to albumin, proteins and nucleic acid aptamers that directly bind to FcRn, any protein with a long half-life, or a combination thereof.

[0023] In another preferred embodiment, X1 and X2 are each independently 0-30 amino acids. In another preferred embodiment, X1, X2 are each independently 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 amino acids.

[0024] In another preferred embodiment, the linker molecules L1, L2 each independently have a bifunctional head and can be coupled to the specific binding sites of the nucleic acids W1, W2 or Y1, Y2 with modified ends having modified groups and T or A or X1, X2. In another preferred embodiment, the active groups of the linker molecules L1 and L2 are each independently selected from maleimide, a haloacetyl group, and a thiopyridine.

[0025] In another preferred embodiment, the haloacetyl group is selected from an iodoacetyl group and a bromoacetyl group. In another preferred embodiment, the drug element moiety, T, is a protein-based drug element. In another preferred embodiment, the protein-based drug element T is wild-type or mutated.

[0026] In another preferred embodiment, the mutation does not affect the function of the drug. In another preferred embodiment, the mutation comprises the introduction of one or more cysteine ​​residues (Cys) into the protein drug element. In another preferred embodiment, the cysteine ​​residue is located at any position of the protein drug element (eg, at the N-terminus, C-terminus, or any position within).

[0027] In another preferred embodiment, the mutation comprises the introduction of one or more cysteine ​​residues at the carboxy terminus (C-terminus) of the protein drug element (eg, an antibody). In another preferred embodiment, the cysteine ​​residue is for linking to DNA. In another preferred embodiment, the protein-based drug element is FVIII.

[0028] In another preferred embodiment, Y1 and Y2 are each independently 0-30 nucleotides. In another preferred embodiment, said Y1 and Y2 are each independently an L-nucleic acid.

[0029] In another preferred embodiment, Y1, Y2 are each independently 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 nucleotides. In another preferred embodiment, Y1 and Y2 are each independently AAAA, AAA or AA.

[0030] In another preferred embodiment, Z1 and Z2 are each independently 0-30 nucleotides. In another preferred embodiment, said Z1 and Z2 are each independently an L-nucleic acid.

[0031] In another preferred embodiment, Z1, Z2 are each independently 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29 or 30 nucleotides. In another preferred embodiment, Z1 and Z2 are each independently AAAA, AAA or AA.

[0032] In another preferred embodiment, said nucleic acids W1, W2 are L-nucleic acids. In another preferred embodiment, the nucleic acids W1 and W2 are selected from DNA and RNA.

[0033] In another preferred embodiment, the modifying group is selected from the group consisting of NH2, an alkynyl group, a mercapto group (SH), a carboxy group (COOH), or a combination thereof. In another preferred embodiment, the modifying group is NH2. In another preferred embodiment, the position of the modifying group in the nucleic acid W1, W2 and / or Y1, Y2 is selected from the 5' end, the 3' end, and any intermediate position.

[0034] In another preferred embodiment, there is a transition region having a length of 0-10 nt between any two complementary paired regions in the nucleic acids W1 and W2. In another preferred embodiment, the transition region is AAAA, AAA, or AA. In another preferred embodiment, the length of the complementary pairing region is 5 to 100 nt, preferably 8 to 50 nt, more preferably 10 to 30 nt, even more preferably 12 to 25 nt, and most preferably 16 to 20 nt.

[0035] In a second aspect of the invention, there is provided a method for assembling a drug (e.g. a protein drug) with extended half-life, the method comprising the steps of: (a) selecting a drug unit and a half-life extending unit from a drug library according to the first aspect of the invention based on pharmaceutical information; and (b) assembling the drug unit into an extended half-life drug by mixing the drug unit with at least one half-life extending unit;

[0036] In another preferred embodiment, the assembly is performed by complementing the nucleic acid element portions to form a complementary base pairing structure (eg, a double-stranded pairing structure). In another preferred embodiment, in the drug with extended half-life, the nucleic acid element portion of each drug unit forms a complementary base pairing structure (e.g., a double-stranded pairing structure) with the nucleic acid element portion of one, two, or three types of half-life extension units.

[0037] In another preferred embodiment, the assembly is to form a complementary base pairing structure (e.g., a double-stranded pairing structure) by complementation of the single-stranded complementary sequence of the nucleic acid element portion and a complementary nucleic acid molecule (i.e., nucleic acid F). In another preferred embodiment, the complementary nucleic acid molecule is in single-stranded form.

[0038] In another preferred embodiment, the nucleic acid F is a nucleic acid that is not coupled to a protein drug. In another preferred embodiment, the nucleic acid F is an L-nucleic acid or a nucleic acid modified by a modifying group. In another preferred embodiment, the length of the nucleic acid F is 1-1.5 times the total number of nucleic acid pairs of the monomers in all of (b).

[0039] In another preferred embodiment, the pharmaceutical information is information on a protein drug required for treating a disease of a subject to be treated, including the type, administration means, and pharmacokinetics of the protein drug. In another preferred embodiment, the assembly conditions are reacting at 5-50° C. (preferably 25-40° C.) for 1-15 minutes (preferably 5-10 minutes). In another preferred embodiment, the assembly condition is pH 6-8.

[0040] In a third aspect of the present invention, there is provided a drug having an extended half-life, the drug having an extended half-life being formed by nucleic acid complementation between a drug unit and n types of half-life extension units to form a complementary base pairing structure (e.g., a double-stranded pairing structure), where n is a positive integer ≧1, Here, the drug unit comprises a drug element portion and a first nucleic acid element portion linked to the drug element portion, the half-life extension unit comprises a half-life extension element portion and a second nucleic acid element portion linked to the half-life extension element portion, and the nucleic acid element portion of one of the drug unit monomers is complementary to the nucleic acid element portion of at least one half-life extension unit to form a complementary base pairing structure (e.g., a double-stranded pairing structure).

[0041] In another preferred embodiment, the nucleic acid element portion is resistant to nuclease degradation. In another preferred embodiment, the drug is a protein drug, and the protein drug has a structure represented by Formula I: [ka] (however, T0 is a protein drug. L0 is a nucleic acid linking element for linking T0 and A0. A0 is an FcRn binding element, or a binding element that binds to an FcRn binding protein (eg, serum albumin). n is a positive integer ≧1.

[0042] In another preferred embodiment, the nucleic acid element portion is an L-nucleic acid, a peptide nucleic acid, a locked nucleic acid, a thio-modified nucleic acid, a 2'-fluoro-modified nucleic acid, a 5'-amino acid, -Hydroxymethylcytosine Nucleic Acid or a combination thereof. In another preferred embodiment, the Drug unit and the half-life extending unit are a Drug unit and a half-life extending unit from a drug library according to the first aspect of the present invention.

[0043] In another preferred embodiment, the drug with extended half-life is a multimeric protein drug, which is a multimer in which D types of protein drug monomers form a complementary base pairing structure (e.g., a double-stranded pairing structure) through nucleic acid complementation, where D is a positive integer ≧2. In another preferred embodiment, D is a positive integer from 2 to 6, preferably D is 2, 3, 4 or 5.

[0044] In another preferred embodiment, the half-life extended drug is a half-life extended protein drug. In another preferred embodiment, the half-life extended protein drug has a half-life H1 of degradation in the body that is greater than the half-life H2 of a single protein drug element in the body. In another preferred embodiment, the ratio value of H1 / H2 is 1-100, preferably 10-50, more preferably 10-20.

[0045] In a fourth aspect of the present invention, (i) as an active ingredient, an extended half-life drug according to the third aspect of the invention; (ii) a pharma- ceutically acceptable carrier; The present invention provides a pharmaceutical composition comprising: In another preferred embodiment, the dosage form of the pharmaceutical composition is selected from the group consisting of an injection and a freeze-dried preparation.

[0046] Of course, it is understood that within the scope of the present invention, the above technical features of the present invention and the technical features specifically described below (for example, in the Examples) can be combined with each other to form new or preferred technical solutions, which will not be described here one by one due to space limitations. [Brief description of the drawings]

[0047] FIG. 1 shows a diagram of the mechanism by which the half-life of a drug is extended by nucleic acid pairing in the present invention. FIG. 2 shows the structure of a protein drug linked to an FcRn targeting unit in one embodiment of the present invention. FIG. 3 shows the agarose gel electrophoresis patterns before and after four different L-DNA single strands are organized into a tetramer backbone. FIG. 4 shows the half-life of long-acting blood coagulation factor VIII in a mouse model of hemophilia. FIG. 5 shows the SDS-PAGE electrophoresis patterns of purified HSAmb protein and HSAmb-DNA ligation. FIG. 6 shows the SDS-PAGE electrophoresis pattern of the result of assembling long-acting FVIII. Here, (a) is the SDS-PAGE electrophoresis pattern of the result of assembling long-acting FVIII. Lane 1: FVIII. FVIII powder was dissolved in ddH2O, and the buffer was replaced with PBS pH 7.4 by desalting to a final concentration of 133 IU / ml. 10 μl was taken and loaded onto SDS-PAGE. Lane 2: FVIII-L-DNA ligation result. FVIII with a final concentration of 133 IU / ml was ligated with L-DNA1-(PEG)2-MAL at a ratio of 1:4 (reacted at 25 degrees for 2 hours) to obtain FVIII-DNA1 sample. 10 μl was taken and loaded onto SDS-PAGE. Lane 3: FVIII-HSAnb ligation result. HSAmb-DNA4, L-DNA2 and L-DNA3 were added to the FVIII-DNA1 sample in order and mixed. The molar ratio of L-DNA1, L-DNA2, L-DNA3 and L-DNA4 in the reaction system was 1:1:1:1 to obtain long-acting FVIII. 10 μl was taken and loaded onto SDS-PAGE. Lane 4: Protein molecular weight standard. (b) is a schematic diagram of the structure of FVIII-HSAnb after assembly. FIG. 7 shows the results of measuring the in vitro activity APTT of samples FVIII, FVIII-L-DNA1, and FVIII-HSAnb. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0048] Through extensive and in-depth research, the present inventors have for the first time developed a drug with extended half-life and its library, as well as its preparation and use. By using the drug library and preparation method of the present invention, drugs with extended half-life can be assembled quickly, efficiently, at low cost and with high yield as required. Based on this, the present invention has been completed. Specifically, the present invention provides a drug with an extended half-life, comprising (a) a drug unit, and (b) n half-life extension units coupled to the drug unit by complementary bases of nucleic acid, wherein the drug unit comprises a drug element portion and a first nucleic acid element portion linked to the drug element portion, the half-life extension unit comprises a half-life extension element portion and a second nucleic acid element portion linked to the half-life extension element portion, and the nucleic acid element portion of one of the drug unit monomers forms a complementary base pairing structure (e.g., a double-stranded pairing structure) with the nucleic acid element portion of at least one of the half-life extension units by complementation, where n is a positive integer of ≧1. The drug with an extended half-life of the present invention only requires rapid assembly (e.g., within 1 minute) to form a stable complementary base pairing structure of nucleic acid (not complex peptide bonds or other chemical modifications, etc.). In experiments, the drug of the present invention can specifically bind to FcRn through an FcRn-binding element or a binding element that binds to an FcRn-binding protein (e.g., serum albumin). Unexpectedly, after being taken up by hematopoietic cells or vascular endothelial cells in blood by pinocytosis, the drug of the present invention enters endosomes and binds to FcRn therein, thereby entering the recovery pathway and surviving degradation in many environments, such as intracellular and endosomal. In this way, the drug of the present invention can effectively enter the degradation pathway and avoid being degraded by lysosomes. In addition, when the drug of the present invention circulates to the cell surface, it dissociates with FcRn under neutral physiological conditions (e.g., about pH 7.4) and is released into the blood, thereby realizing circulatory utilization (see FIG. 1).

[0049] term Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by those skilled in the art to which the present invention belongs. As used herein, when used with a specific exemplified numerical value, the term "about" means that the value may vary within 1% from the exemplified numerical value. For example, as used herein, the expression "about 100" includes 99 and 101 and all values ​​therebetween (e.g., 99.1, 99.2, 99.3, 99.4, etc.).

[0050] Although any methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention, the preferred methods and materials are described herein.

[0051] As used herein, the terms "protein drug" and "polypeptide drug" refer to drugs that contain amino acids and form a polypeptide sequence via peptide bonds, and may be used interchangeably, and may consist only of an amino acid sequence or may consist essentially of an amino acid sequence. The terms also include protein drugs in unmodified or modified forms, such as glycosylated protein drugs, PEGylated protein drugs, and ADC forms.

[0052] As used herein, the terms "half-life extension unit", "half-life extension module", and "half-life enhancing module" can be used interchangeably to refer to an element or module that contains a half-life extension element portion and a second nucleic acid element portion linked to the half-life extension element portion, and forms a "drug unit-half-life extension unit" complex through complementary bases, further extending the half-life of the protein drug complex.

[0053] As used herein, the terms "protein-drug conjugate" and "drug unit-half-life extending unit conjugate" refer to a drug conjugate formed by a drug unit and a half-life extending unit via complementary bases, and may be used interchangeably.

[0054] Drug T In the present invention, the drug unit comprises a drug element portion and a first nucleic acid element portion linked to the drug element portion. Here, the drug element portion is a protein-based drug or a polypeptide-based drug.

[0055] Typically, said protein-based drugs include, but are not limited to, antibodies, fusion proteins, growth factors, hormones (eg, insulin, growth hormone, etc.). In one preferred embodiment of the present invention, the protein-based drug is long-acting factor VIII (FVIII) for treating hemophilia A.

[0056] Half-life extension unit A In the present invention, the half-life extension unit comprises a half-life extension element portion and a second nucleic acid element portion linked to the half-life element portion. Specifically, the present invention utilizes a multispecific antibody self-assembly technology mediated by nucleic acid pairing (patent application number 201710322583.3), in which a protein or polypeptide (half-life extender) targeting FcRn and a drug are each linked to a nucleic acid element to form an FcRn targeting unit, and then the two are coupled together through complementary pairing of the nucleic acid element to form a long-acting drug that is recovered by cells. The half-life extension element portion (half-life extension factor) is divided into several types:

[0057] 2.1 HSA protein The HSA protein can be HSA extracted from blood or recombinantly expressed by a low-cost expression system such as yeast. HSA has one free Cys34, which is useful for single-stranded, degradation-resistant nucleic acids (e.g., reverse nucleic acids) after activation by site-specific coupling. Of course, the NH2 on the HSA surface is also useful for random coupling of single-stranded nucleic acids when site-specific coupling is not required.

[0058] 2.2 HSA-binding proteins Types of HSA binding proteins include nanobodies, single chain antibodies, Fab and full length IgG antibodies. According to the present invention, the preferred HSA binding proteins are nanobodies and single chain antibodies, which are low cost.

[0059] 2.3 HSA-binding polypeptides and domains Polypeptides of specific sequences, such as polypeptide SA21 (amino acid sequence: Ac-RLIEDICLPRWGCLWEDD-NH2, SEQ ID NO: 6) can also bind to HSA, in which the core sequence is DICLPRWGCLW (SEQ ID NO: 7), and any polypeptide containing the core sequence can bind to HSA to different degrees and become the half-life enhancer of the present invention patent. Domains of other proteins, for example engineered small fragment antibodies such as Affibodies, DARTs, etc., can also be made into HSA binding protein domains by targeted engineering, evolution, etc.

[0060] 2.4 HSA-binding nucleic acids Some nucleic acid aptamers can specifically bind to HSA, for example, one RNA-type nucleic acid aptamer sequence is 5'-GUGGACUAUACCGCGUAAUGCUGCCUCCAC-3' (SEQ ID NO: 8). In view of the difficulty of synthesis and production, the preferred HSA-binding nucleic acid of the present invention is preferably consistent with the type of nucleic acid framework, for example, it may be L-RNA or L-DNA at the same time.

[0061] Furthermore, nucleic acids modified with dendritic alkyl chains can also bind to HSA. For example, J. Am. Chem. Soc. 2017.139.21.7355-7362 reports a DNA cube consisting of a DNA assembly modified with dendritic alkyl groups that can bind to HSA with high affinity.

[0062] For protein or polypeptide half-life extenders, a specific site (e.g., a mutation site, Cys) may be introduced into the half-life extender to facilitate binding to activated L-nucleic acid and used for coupling of the linker. For nucleic acid-based half-life extenders, the sequence can be incorporated into the same type of nucleic acid for assembly and synthesised simultaneously.

[0063] Drug Library The present invention relates to a drug library, comprising: (a) a Drug unit; and (b) n half-life extension units, wherein the drug unit comprises a drug element portion and a first nucleic acid element portion linked to the drug element portion; the half-life extension unit comprises a half-life extension element portion and a second nucleic acid element portion linked to the half-life element portion; and the first nucleic acid element portion of one of the drug units and the second nucleic acid element portion of at least one of the half-life extension units form a complementary base pairing structure (e.g., a double-stranded pairing structure) to form a "drug unit-half-life extension unit" complex, Here, n is provided as a positive integer ≧1.

[0064] As used herein, the term "complementary" includes pairing by complementation or forming a complementary base pairing structure (e.g., a double-stranded pairing structure) through a single-stranded complementary sequence of one or more (e.g., 2, 3, 4, 5, 6) auxiliary complementary nucleic acid molecules (i.e., nucleic acid F).

[0065] In one preferred embodiment of the invention, the auxiliary complementary nucleic acid molecule (ie, nucleic acid F) is a multimerized auxiliary molecule (strand). In one preferred embodiment of the present invention, the drug unit and the half-life extension unit form a multimer in the presence of the multimerization auxiliary molecule (chain). Typically, the term "complementary" refers to pairing by direct complementation.

[0066] In one preferred embodiment of the present invention, the term "complementary" refers to forming a complementary base pairing structure through complementation via a single-stranded complementary sequence of one complementary nucleic acid molecule (i.e., nucleic acid F). In another preferred embodiment of the present invention, the "complementary" refers to the formation of a complementary base pairing structure through complementation via the single-stranded complementary sequences of two complementary nucleic acid molecules (i.e., nucleic acid F) (as shown in FIG. 2).

[0067] The library of the present invention contains at least one Drug unit and at least one half-life extending unit, said Drug unit and half-life extending unit being assembled to form a Drug, and a preferred Drug has the structure of Formula I above. In another preferred embodiment of the present invention, the library of the present invention contains at least one Drug unit and at least one (eg, two, three, four) half-life extending units.

[0068] Typically, the Drug unit has the structure of Formula II above. Typically, the half-life extending unit has the structure of Formula III above.

[0069] Due to the specific structure of the drug unit and half-life extending unit of the present invention, not only can they be rapidly assembled into drugs, but the formed drugs also have unexpectedly extended half-lives (significantly increased stability in the body), remain active in the body for a long time, and are not quickly decomposed.

[0070] For example, in the treatment of cancer (or other metabolic diseases), multiple targets and multiple pathways are often involved, and each patient has a different etiology, different constitution, different age, and a single patient may have tumor heterogeneity or different disease subtypes, and the pharmacokinetics and metabolic pathways are often different, so it is often necessary to use drugs with different half-lives for multiple targets. With the development of personalized medicine or precision medicine technology, the field has a strong demand for protein drugs (such as multispecific antibodies) that can be produced quickly, are low-cost, have good targeting, good stability, and have controllable (adjustable) half-lives. The library of the present invention meets such demands.

[0071] Of course, the drug library of the present invention contains, mainly contains, or entirely contains the above drug units and half-life extending units of the present invention, but the drug library also contains other therapeutic agents, particularly other protein drugs, representative examples of which include, but are not limited to, antibodies, chemical compounds, and fusion proteins. For example, the library of the present invention may contain a conventional antibody having one or more additional therapeutic effects, or a conventional drug that extends the half-life of a drug, or a conventional metabolic regulator.

[0072] Of course, the number of half-life extending units in the library of the present invention is not limited, but may be any positive integer n ≧ 2. For example, n is any positive integer from 3 to 100, preferably 3 to 50, more preferably 5 to 20, and most preferably 5 to 8. Furthermore, in the present invention, the antibody element in the half-life extension unit is not particularly limited, and representative examples are selected from the group consisting of single chain antibodies, nanobodies, Fab, monoclonal antibodies, or combinations thereof.

[0073] In the library of the present invention, drug units can be prepared from proteins and polypeptides of various origins. The half-life extension units can be produced from antibodies of various origins. One prominent feature of the drug library of the present invention is that the production costs can be significantly reduced by using antibody fragments expressed by prokaryotic systems (e.g., E. coli) or eukaryotic systems (e.g., yeast, CHO cells).

[0074] Typically, when in use, the corresponding drug units and half-life extending units can be selected (including types and numbers) according to need (e.g., information on the protein drug required to treat the disease of the subject to be treated, including the pathology and diagnosis results of an individual, the type of protein drug, administration means, and pharmacokinetics), and the drug assembly can be easily completed by the nucleic acid complementary framework. For example, in application, the number or ratio of half-life extending units (e.g., 2 types, 3 types, 4 types, or more than 4 types) can be determined according to the target disease status and metabolic status of the patient, and then assembled.

[0075] When producing a drug, the corresponding drug unit and half-life extension unit that can be coupled to each other directly or indirectly are selected from the library, and then mixed in the required antibody ratio, and the assembly process can be completed within one minute. In the library of the present invention, the nucleic acid elements of the drug units and the nucleic acid elements of the half-life extension units can be designed into a multimer framework such as a dimer, trimer, or tetramer through sequence design, thereby making it possible to complete the production of multimers in which a single drug molecule has three or even four half-life extension units, which is difficult to achieve using conventional drug half-life design and production technologies. Once assembled into a multimeric protein drug, it can be administered to appropriate individuals for therapeutic purposes.

[0076] L-nucleic acid L-nucleic acids are mirror images of D-nucleic acids found in nature, and are divided into L-DNA and L-RNA. The left-handed chiral center is mainly present in the deoxyribose or ribose portion of nucleic acids, and rotates mirror-image. Therefore, L-nucleic acids are decomposed by nucleases (e.g. exoribonucleases, endonucleases) that are present everywhere in plasma.

[0077] The half-life extended drug of the present invention The half-life extended drug of the present invention is a half-life extended drug comprising a drug unit and n types of half-life extension units that form a complementary base pairing structure (e.g., a double-stranded pairing structure) through nucleic acid complementation, where n is a positive integer ≧1, where the drug unit comprises a drug element portion and a first nucleic acid element portion linked to the drug element portion, the half-life extension unit comprises a half-life extension element portion and a second nucleic acid element portion linked to the half-life extension element portion, and the nucleic acid element portion of one of the drug unit monomers forms a complementary base pairing structure (e.g., a double-stranded pairing structure) through complementation with the nucleic acid element portion of at least one half-life extension unit.

[0078] In another preferred embodiment, the nucleic acid element portion is resistant to nuclease degradation. In another preferred embodiment, the nucleic acid element portion is an L-nucleic acid, a peptide nucleic acid, a locked nucleic acid, a thio-modified nucleic acid, a 2'-fluoro-modified nucleic acid, 5-Hydroxymethylcytosine Nucleic Acid or a combination thereof.

[0079] The drug of the present invention can be formed, for example, by assembling a drug unit represented by formula II and a half-life extending unit represented by formula III. Typically, a multimeric drug comprises a drug unit and multiple half-life extension units assembled together, for example a di-, tri-, tetra-, penta- or hexamer.

[0080] In one preferred embodiment, the drug of the present invention is linked by using L-nucleic acid.The present study shows that, because nucleic acid is a double-stranded molecule that can rapidly and specifically pair, by coupling half-life extension element part (such as HSA, single-stranded antibody, nanobody, Fab, etc.) with single-stranded nucleic acid, and coupling drug element part with single-stranded nucleic acid, two or more single-stranded nucleic acids can be rapidly paired by designing nucleic acid sequence, so that drug unit can be rapidly assembled with one or more half-life extension units, and the production of drug with extended half-life can be completed.

[0081] In the present invention, in order to realize the effect of extending the half-life of a drug, it is necessary to use a drug unit and a half-life extension unit with a specific structure.In a preferred embodiment, the half-life of a drug can be significantly improved by using L-nucleic acid (such as L-DNA, L-RNA, etc.) instead of D-nucleic acid (such as D-DNA, D-RNA, etc.).One reason is that L-nucleic acid is not degraded by exoribonucleases, endonucleases, etc. present in the human body, so the drug produced by the self-assembly of L-nucleic acid is very stable in the body.

[0082] Manufacturing method 1. Design and fabrication of L-nucleic acid strand framework According to the invention, the L-nucleic acid chain framework is formed by base pairing of two or more L-nucleic acid single strands. Either the 5' or 3' end of each L-nucleic acid single strand is activated with a group (e.g., NH2, etc.) for subsequent modification, and then one end of a linker (e.g., SMCC, SM(PEG), SPDP, etc.) is coupled to an activated group on the L-nucleic acid single strand. The L-nucleic acid with the linker can be assembled into the required L-nucleic acid chain framework. After it has been confirmed that the L-nucleic acid with the linker can self-assemble into the framework, the L-nucleic acid single strand with the linker is linked to an antibody, respectively, for subsequent assembly.

[0083] The L-nucleic acid framework of the present invention can basically be produced by the following steps. 1.1 Design of single stranded L-nucleic acid capable of rapid self-assembly Determine the number N of half-life enhancing modules required (e.g., 3 half-life enhancing modules), determine the number M (M≧N+1) of L-nucleic acid single strands required according to the number N of half-life enhancing modules, design a corresponding number of L-nucleic acid single strand sequences, and adjust the stability of the target nucleic acid framework by increasing or decreasing the number of base pairings, thereby reducing the possibility of non-specific pairing between nucleic acid strands.

[0084] According to a preferred embodiment of the present invention, in order to design a tetrameric L-nucleic acid framework (M=4), four L-nucleic acids (shown in FIG. 2) that pair according to a certain rule are designed. Here, any one L-nucleic acid single strand pairs specifically and complementary with the other two L-nucleic acid single strands, but does not pair with the fourth strand. The absolute value of the Gibbs energy change ΔG of the specific complementary pairing is much larger than that of nonspecific pairing. For example, in the preferred embodiment, the absolute value of the Gibbs energy change ΔG of the specific complementary pairing of each arm is about 26 kcal / mol, while the nonspecific pairing is smaller than 7 kcal / mol, which indicates that the assembly of the tetramer is more likely to occur than nonspecific pairing between two units, and the tetrameric form is the most stable in the reaction system. The tetrameric L-nucleic acid framework can link 1-3 half-life enhancers.

[0085] 1.2 Activation of L-DNA or L-RNA The activation of L-nucleic acid involves the modification of the active group at its 5'-end or 3'-end and the subsequent coupling of a linker. The active group modification can be completed custom-made by a nucleic acid synthesis company. The linker usually has a dual functional group, i.e., one end can be coupled to the active group of the nucleic acid, and the other end can be linked to a specific site (e.g., SH) on an antibody.

[0086] According to one preferred embodiment of the present invention, all L-nucleic acids that will become the framework are modified with NH2 at the 5' end, and then coupled to NH2 in the nucleic acid via an amide bond using a linker, i.e., a bispecific heterofunctional crosslinking reagent SMCC (4-(N-maleimidomethyl)cyclohexane-1-carboxylic acid N-succinimidyl sodium salt). At this time, the maleimide group at the other end of the linker is free and can be used for coupling with a mercapto group (SH) in the antibody later, completing the activation of the L-nucleic acid.

[0087] 2. Method for producing antibody-L-nucleic acid complex First, the 5' or 3' end of the L-nucleic acid is modified with NH2, and then a linker can be used, which can be one of the following main preparation methods: the functional group at one end of the linker is NHS (N-hydroxysuccinimide) or Sulfo-NHS (N-hydroxysulfosuccinimide sodium), so as to be rapidly coupled to the NH2 group at one end of the L-nucleic acid. Any linker containing a bispecific functional group first reacts with the NH2 of the L-nucleic acid, and then reduces the sulfhydryl group in the antibody, after which the group at the other end reacts with the sulfhydryl group to form a stable chemical bond.

[0088] 2.1 Maleimide. The group of the linker for coupling with the sulfhydryl group of the antibody is maleimide. Maleimide reacts rapidly with the free sulfhydryl group of the antibody to form a sulfide bond. Common linkers include SMCC (4-(N-maleimidomethyl)cyclohexane-1-carboxylate N-succinimidyl), SM(PEG) (polyethylene glycol modified 4-(N-maleimidomethyl)cyclohexane-1-carboxylate N-succinimidyl), etc.

[0089] 2.2 Haloacetyl group. The group for coupling with the sulfhydryl group of the antibody of the linker is a haloacetyl group, such as an iodoacetyl group or a bromoacetyl group. The halide ion can displace the sulfhydryl group of the antibody by nucleophilic action to form a sulfide bond. Common linkers include SBAP (N-maleimidomethyl [4-bromoacetyl] aminobenzoate) and SIAB (N-maleimidomethyl [4-iodoacetyl] aminobenzoate).

[0090] 2.3 Thiopyridine (Pyridyldithiol). The group for coupling with the sulfhydryl group in the antibody of the linker is thiopyridine. Thiopyridine can react with free sulfhydryl groups to form disulfide bonds. Common linkers include SPDP (3-(2-pyridinedithio)propionic acid N-hydroxysuccinimide ester).

[0091] Drug Composition Furthermore, the present invention provides a composition. In a preferred embodiment, the composition is a pharmaceutical composition, which contains the above-mentioned antibody or its active fragment or its fusion protein, and a pharma- ceutically acceptable carrier. Usually, these substances are formulated in a non-toxic, inert, pharma-ceutically acceptable aqueous carrier, and the pH value is usually about 5 to 8, preferably about 6 to 8, depending on the nature of the substance to be formulated and the disease to be treated. The formulated pharmaceutical composition can be administered by a conventional route, including, but not limited to, oral, airway, intratumoral, intraperitoneal, intravenous, or local administration.

[0092] The pharmaceutical composition of the present invention can be used directly for treatment (for example, antitumor treatment), and is therefore useful for extending the half-life of the drug and for use in combination with other therapeutic agents. The pharmaceutical composition of the present invention comprises a safe and effective amount (e.g., 0.001-99 wt%, preferably 0.01-90 wt%, more preferably 0.1-80 wt%) of the above-mentioned monoclonal antibody of the present invention (or a complex thereof) and a pharma- ceutically acceptable carrier or excipient. Such carriers include, but are not limited to, saline, buffer, glucose, water, glycerin, ethanol, and combinations thereof. The pharmaceutical formulation corresponds to the administration form. The pharmaceutical composition of the present invention may be an injection, which can be prepared by a conventional method, for example, in physiological saline or an aqueous solution containing glucose and other auxiliary agents. In the case of an injection or solution, the pharmaceutical composition is prepared under aseptic conditions. The dosage of the active ingredient is a therapeutically effective amount, for example, about 1 μg / kg body weight to about 10 mg / kg body weight daily. The polypeptide of the present invention can also be used in combination with other therapeutic agents.

[0093] When using the pharmaceutical composition, a safe and effective amount of the immunoconjugate is administered to a mammal, and the safe and effective amount is usually at least about 10 μg / kg body weight, and in many cases, less than about 50 mg / kg body weight, and preferably the dosage is about 10 μg / kg body weight to about 1 mg / kg body weight. Of course, the specific dosage should further take into account factors such as the mode of administration and the health condition of the patient, all of which are within the skill of a skilled physician.

[0094] The main advantages of the present invention are: (1) The half-life extension module of the present invention can complete assembly with a target protein via an L-nucleic acid chain within one minute. (2) The half-life extension factor in the half-life enhancing module of the present invention has a wide range of possibilities for modification, and can be selected from HSA or any form of HSA binding protein, small molecule and polypeptide (e.g., HSA single chain antibody, nanobody, Fab). (3) The half-life enhancing module of the present invention can be stored separately for use, and can be coupled to respective protein or polypeptide drugs by simple nucleic acid synthesis and assembly. (4) The half-life extension module of the present invention can flexibly adjust the pharmacokinetic properties by producing a long half-life drug containing a different number of half-life extension modules as needed. (5) The half-life extension factors in the half-life extension module of the present invention are all proteins or polypeptides that are low-cost and easy to produce, such as anti-HSA nanobody that can be expressed in E. coli and HSA protein, which has a high concentration of 50 g / L in human blood. Therefore, the long-acting drugs produced based on the module have the advantages of being easy to produce, highly versatile, and low-cost. (6) The present invention provides a method for flexibly linking a drug to an FcRn targeting factor, and its use in extending the half-life of a drug in an animal body via the FcRn-mediated drug recovery pathway.

[0095] The present invention will be further described below with reference to specific examples. It is understood that these examples are only used to illustrate the present invention and do not limit the scope of the present invention. Experimental methods for which specific conditions are not shown in the following examples are usually performed according to standard conditions, such as those described in Sambrook et al., "Molecular Cloning: A Laboratory Manual" (New York, Cold Spring Harbor Laboratory Press, 1989), or according to the manufacturer's recommended conditions. Unless otherwise specified, percentages and parts are calculated by weight. All experimental materials according to the present invention were obtained as commercially available products unless otherwise specified.

[0096] Example 1: Design of the framework for the tetrameric DNA structure We designed L-nucleic acids (shown in Figure 2) that pair in a quadrangular shape. Here, any one L-nucleic acid single strand pairs specifically with two other L-nucleic acid single strands, but does not pair with the fourth strand. The absolute value of the Gibbs energy change ΔG of the specific complementary pairing is much larger than that of the nonspecific pairing, and the absolute value of the Gibbs energy change ΔG of the specific complementary pairing of each arm is larger than 25 kilocalories / mole (kcal / mol), while the nonspecific pairing is smaller than 7 kilocalories / mole (kcal / mol) for all of them. This indicates that the assembly of tetramers is more likely to occur than nonspecific pairing between two units, and that the tetrameric form is the most stable in the reaction system.

[0097] The sequences of the four L-DNA single strands designed based on the above principles are as follows (5' to 3'): Strand 1 (L-DNA1): SEQ ID NO:1 5'-AAGAGGACGCAATCCTGAGCACGAGGTCT-3' Strand 2 (L-DNA2): SEQ ID NO:2 5'-AACTGCTGCCATAGTGGATTGCGTCCTCT-3' Strand 3 (L-DNA3): SEQ ID NO:3 5'-AATGAGTGCATTCGGACTATGGCAGCAGT-3' Strand 4 (L-DNA4): SEQ ID NO:4 5'-AAGACCTCGTGCTCACCGAATGCACTCAT-3'

[0098] The 5' end is modified with an NH2 group so that it can be coupled to the NHS of SMCC. Any single-stranded base sequence complementarily pairs with the other two strands, and the Gibbs energy change ΔG of pairing between each part is approximately -34 kilocalories / mol (kcal / mol).

[0099] Example 2 Synthesis and validation of tetrameric DNA frameworks The L-DNA single strands modified with NH2 at the 5' end were synthesized by a biotechnology service company (eg, Chemgene Inc., Biosyn Inc., etc.), and the sequences of the four single strands are shown in Example 1.

[0100] The single-stranded L-DNA was dissolved in phosphate buffer (50 mM NaH2PO4, 150 mM NaCl, pH 7.0) to prepare a mother solution with a final concentration of 200 μM. SMCC powder was dissolved in dimethyl sulfoxide (DMSO) to prepare a new 250 mM SMCC mother solution. 10 to 50 times the molar amount of SMCC mother solution was added to the single-stranded L-DNA mother solution, and after mixing, the mixture was reacted at room temperature for 30 min to 2 h. After the reaction was completed, 10% volume of 1M Tris-HCl (pH 7.0) was added to the reaction solution, mixed, and incubated at room temperature for 20 minutes to stop the excess SMCC from continuing to react. After the incubation was completed, 100% absolute ethanol was added in a volume twice that of the reaction solution, mixed uniformly, and then placed in a -20 °C refrigerator for 25 minutes to thoroughly precipitate the L-DNA. The precipitate was collected by centrifugation (12000 rpm, 10 min), washed with 1 mL of 70% ethanol, centrifuged at 12000 rpm for 1 min to remove the supernatant, and washed five times to thoroughly remove excess SMCC. The remaining white precipitate was naturally dried in air for 5 to 10 min, then resuspended and dissolved in phosphate buffer to obtain the SMCC-L-DNA complex (i.e., single-stranded SMCC-L-DNA).

[0101] The concentration of each SMCC-L-DNA single strand was measured. An appropriate amount of the four SMCC-L-DNA single strands to be used in the reaction was taken and preheated at 40°C for 5 min, and then equimolar amounts of the four SMCC-L-DNA single strands were mixed and incubated at 40°C for 1 min. 0.25 μl of the SMCC-L-DNA single strands and the reaction products were analyzed by 3% agarose gel electrophoresis.

[0102] As shown in Figure 3, the size of the single stranded SMCC-L-DNA was approximately 25 bp, and the main band formed after mixing was approximately 100 bp, indicating that four different single stranded SMCC-L-DNAs had formed a tetrameric framework.

[0103] Example 3. Preparation of Half-Life Extender-Anti-HSA Nanobody Mutants Cysteine ​​mutations were introduced into the carboxy terminus of the anti-HSA nanobody, and although the nanobody has a disulfide bond, its small molecular weight and extremely stable structure make it possible to express it in the cytoplasm of E. coli. The gene sequence of the anti-HSA nano antibody was optimized to be codon-compatible with E. coli and then subcloned into pET21b plasmid.

[0104] The amino acid sequence of the anti-HSA nanobody is SEQ ID NO: 5. To facilitate purification, all nanobodies were N-terminally twin-Strep-tagged. SEQ ID NO:5, Amino acid sequence of anti-HSA Nanobody mutant: SAWSHPQFEKGGGSGGGSGGSAWSHPQFEKENLYFQSEVQLVESGGGLVQPGNSLRLSCAASGFTFSSFGMSWVRQAPGKGLEWVSSISGSGSDTLYADSVKG RFTISRDNAKTTLYLQMNSLRPEDTAVYYCTIGGSLSRSSQGTLVTVSSGSC

[0105] 1 μl of the constructed expression vector was used to transform E. coli BL21(DE3), a single colony of the transformed BL21(DE3) was inoculated into LB medium (containing 100 μg / mL ampicillin), and cultured at 37 degrees until OD600=0.7. IPTG was added to a final concentration of 1 mM to induce expression, and cultured at 37 degrees for 3 to 4 hours. The cells that were expressed by centrifugation were collected, resuspended in phosphate buffer (50 mM NaH2PO4, 150 mM NaCl, pH 7.0), and a protease inhibitor cocktail (Sigma) (one SIGMAFAST(TM) protease inhibitor tablet was added to the solution and fully dissolved) was added, followed by ultrasonic disruption. DNaseI hydrolase was added and incubated on ice for 1 hour. After the incubation was completed, the bacterial solution was centrifuged at 17,000 rpm for 20 minutes, and the supernatant was collected. The nanoantibodies in the supernatant were purified by Strep affinity column, the supernatant was passed through the column at a rate of 0.25 ml / min, the column was washed with a large amount of Tris buffer (50 mM Tris-HCl, 150 mM NaCl, pH 7.4) at a flow rate of 1 ml / min until no impurity proteins flowed through (from ultraviolet absorption in the AKTA protein chromatography system), and the nanoantibodies bound to the column were eluted with a gradient of Strep-Taction elution buffer (50 mM Tris-HCl, 150 mM NaCl, 2.5 mM dethiobiotin, pH 7.4). RESULTS: Highly purified anti-HSA nanoantibody mutants were obtained.

[0106] Example 4 Nanobody-L-DNA coupling and purification The purified single-chain antibody was incubated with a 10-50 fold molar excess of a reducing agent (e.g., TCEP, DTT, mercaptoethanol, etc.) at room temperature for 30 min. After the incubation, the reducing agent in the reaction system was rapidly removed using a PD-10 desalting column, and the buffer was simultaneously replaced with a phosphate buffer (50 mM NaH2PO4, 150 mM NaCl, pH 7.0). After measuring the concentration of the single-chain antibody, a 1-4 fold molar excess of single-stranded SMCC-L-DNA (prepared in Example 2) was added, mixed uniformly, and reacted at room temperature for 1 h.

[0107] Unreacted and excess SMCC-L-DNA single strands were removed by Strep affinity column, and the nanobody and nanobody-L-DNA mixture were collected. The buffer was replaced with the loading buffer of the anion exchange column.

[0108] Since nucleic acids such as DNA have a negative charge, the nanoantibody-L-DNA was further isolated and purified using an anion exchange column (HiTrap Q HP column) to remove unreacted nanoantibody. The isolation process was achieved by gradient elution, with the loading buffer being 50 mM Tris-HCl, pH 8.5, and the elution buffer being 50 mM Tris-HCl, 1 M NaCl, pH 8.5. Gradient elution was performed with 0-100% elution buffer, and the unreacted nanoantibody and nanoantibody-L-DNA peaks appeared in sequence (Figure 5, lane D10). The nanoantibody-L-DNA was collected and concentrated, and the buffer was replaced with 50 mM NaH2PO4, 150 mM NaCl, pH 7.4 using a PD-10 desalting column.

[0109] Example 5 Self-assembly of half-life enhancing module and target protein drug The following describes the self-assembly process of the half-life enhancing module and the target protein drug by taking the design of a long-acting factor VIII (FVIII) drug for treating hemophilia A as an example. In this embodiment, factor VIII is the target protein drug, and the factor FVIII can be blood-derived factor VIII extracted from human blood, or recombinant factor VIII obtained by genetic engineering.

[0110] Factor VIII was mixed with a 10-50 fold molar excess of a reducing agent (e.g., TCEP, DTT, mercaptoethanol, etc.) and incubated at room temperature for 30 min. After the incubation, the reducing agent in the reaction system was rapidly removed using a PD-10 desalting column, and the buffer was replaced with a phosphate buffer (50 mM NaH2PO4, 150 mM NaCl, pH 7.0) at the same time. After measuring the concentration of factor VIII, a 1-4 fold molar excess of SMCC-L-DNA single strand (prepared in Example 2) was added, mixed uniformly, and reacted at room temperature for 1 h. The product after the reaction was the drug unit: factor VIII-L-DNA. As shown in Figure 6a, the band of the drug unit after the reaction shifted upward.

[0111] The concentrations of anti-HSA nano antibody-L-DNA and factor VIII-L-DNA were measured respectively. After taking an appropriate amount of the above components and preheating at 40 degrees for 5 min, HSA nano antibody-L-DNA and factor VIII-L-DNA were mixed in a 1:1 molar ratio at 40 degrees and incubated for 1 min. This completed the assembly of FVIII-HSAnb, which contains a half-life enhancing module and a factor VIII active part, i.e., long-acting factor VIII. The schematic structure of the assembled FVIII-HSAnb is shown in Figure 6b. As shown in Figure 6a, the bands of the drug unit (factor VIII-L-DNA) and long-acting factor VIII after the reaction shifted upward.

[0112] Activity measurements were performed on samples containing equal amounts of FVIII protein using an APTT kit (Sun Biotechnology). The results are shown in Figure 7. FVIII-L-DNA1 had activity close to that of the unreacted drug unit, while long-acting FVIII had significantly improved activity (~50%).

[0113] The half-life extension effect of FVIII-HSAnb in vivo was examined in 6-8 week old FVIII-deficient mice. Eight mice were randomly divided into an experimental group and a control group, and FVIII-HSAnb and FVIII were intravenously injected at a dose of 5 IU / mouse. Blood was collected on the day before administration, 5 min, 30 h, 48 h, 60 h, 72 h, and 96 h after administration. Plasma was immediately separated after blood collection and frozen and stored in a -80°C refrigerator. After all plasma samples were obtained, FVIII activity was detected by the APTT method.

[0114] From the calculations, FVIII and FVIII-HSAnb had half-lives of 5.6 h and 22.7 h, respectively (shown in FIG. 4). Therefore, the FVIII-HSAnb designed using the present invention can extend the half-life by about four times compared to normal FVIII.

[0115] Consider IgG monoclonal antibodies have the longest half-life of any immunoglobulin antibody, reaching 21 days, and are therefore the main type of therapeutic antibody currently used.

[0116] The long half-life and high serum concentration of IgG monoclonal antibodies are achieved by binding to the neonatal receptor (FcRn) and entering metabolic regulation through it. The Fc portion of IgG can bind to FcRn in a specific pH-dependent manner. When IgG monoclonal antibodies are taken up by hematopoietic cells or endothelial cells in the blood by pinocytosis, they enter endosomes and bind to FcRn there, entering the salvage pathway, and avoiding being degraded by lysosomes by entering the degradative pathway, circulating to the cell surface, and then dissociating from FcRn under neutral physiological conditions (pH 7.4) and being released into the blood.

[0117] Albumin is another protein that binds to FcRn to extend its half-life, which reaches 19 days. Human serum albumin is divided into four domains, I-IV, of which domain III is the part that binds to FcRn, and domain I contains one free cysteine ​​residue (Cys 34). For protein or polypeptide drugs that require a long half-life, such as cytokine drugs, blood clotting factors, etc., Fc and FcRn binding proteins such as HSA are the preferred choice.

[0118] The method of extending half-life by Fc or HSA fusion proteins creates a new epitope at the fusion site of the protein or polypeptide of interest with the given Fc / HSA. In addition, Fc can only be fused to the C-terminus, and HSA can only be fused to the N-terminus or C-terminus of the protein or polypeptide of interest. In addition, the method is not suitable for naturally occurring proteins or polypeptides.

[0119] In the present invention, for the first time, a chemical coupling method has been developed that utilizes chemical molecules or linkers to specifically heterologously couple proteins or polypeptides to FcRn binding modules (such as HSA or HSA binding modules) to extend the half-life of protein drugs and improve their pharmacokinetic properties.

[0120] Compared to Fc or HSA fusion proteins, the methods of the present invention provide a flexible approach that allows for site-specific or non-site-specific modifications of various groups (e.g., SH, NH2, active groups in unnatural amino acids, etc.) of a protein or polypeptide of interest, as well as the modification of native proteins or polypeptides. Furthermore, no or essentially no new epitopes are introduced by the methods of the present invention.

[0121] All documents related to the present invention are incorporated herein by reference as if each document were incorporated individually. After reading the above content of the present invention, it will be understood that those skilled in the art can make various changes and modifications to the present invention, and that equivalent forms thereof are within the scope of the claims of the present invention.

Claims

1. A drug library comprising: (a) a drug unit; and (b) n half-life extension units; wherein the drug unit comprises a drug element portion and a first nucleic acid element portion linked to the drug element portion; the half-life extension unit comprises a half-life extension element portion and a second nucleic acid element portion linked to the half-life element portion; and the first nucleic acid element portion of one of the drug units and the second nucleic acid element portion of at least one half-life extension unit form a complementary base pairing structure to form a "drug unit-half-life extension unit" complex; where n is a positive integer ≧1, The Drug Unit has a structure according to Formula II: 【Chemistry 1】 The drug library, wherein the half-life extending unit has a structure represented by formula III. 【Chemistry 2】 (In the formula, T is the drug element moiety. A is a half-life extending element moiety. X1 and X2 are each independently none or overlapping peptides. L1 and L2 each independently represent a linker molecule. Y1, Y2 and Z1, Z2 are each independently null or overlapping nucleic acids. W1 and W2 are each independently a nucleic acid sequence selected from the group consisting of an L-nucleic acid, a locked nucleic acid, a thio-modified nucleic acid, a 2'-fluoro-modified nucleic acid, a 5-hydroxymethylcytosine nucleic acid, or a combination thereof. "-" is a conjugated bond. Here, the nucleic acid W1 of the drug unit has at least one complementary pairing region, and the nucleic acid W2 of the half-life extension element has at least one complementary pairing region, and the two are partially or completely complementary.

2. The drug library of claim 1, wherein the drug element portion is selected from the group consisting of antibodies, ligands that activate or inhibit receptors or proteins, biologically active enzymes, nucleic acid drugs, small molecule drugs, or combinations thereof.

3. The drug library according to claim 1, wherein the half-life extension element portion is selected from the group consisting of natural albumin, recombinant albumin, anti-albumin antibodies (including nanobodies, single-chain antibodies, Fabs, and monoclonal antibodies), nucleic acid aptamers that specifically bind to albumin, proteins and nucleic acid aptamers that directly bind to FcRn, any proteins with long half-life, or combinations thereof.

4. The drug library of claim 1, wherein the linker molecules L1 and L2 each independently have a dual functional head and can be coupled to the specific binding sites of the nucleic acids W1, W2 or Y1, Y2 with modified ends having modified groups and T or A or X1, X2.

5. A method for assembling a drug (e.g., a protein drug) with extended half-life, comprising: (a) selecting a drug unit and a half-life extending unit from the drug library of claim 1 based on pharmaceutical information; and (b) assembling said drug units into an extended half-life drug by mixing said drug units with at least one half-life extending unit; The method according to claim 1, further comprising:

6. A drug having an extended half-life, the drug being formed by nucleic acid complementation between a drug unit and n types of half-life extension units to form a complementary base pairing structure (e.g., a double-stranded pairing structure), wherein n is a positive integer ≧1; wherein the drug unit comprises a drug element portion and a first nucleic acid element portion linked to the drug element portion, the half-life extension unit comprises a half-life extension element portion and a second nucleic acid element portion linked to the half-life extension element portion, and the nucleic acid element portion of one of the drug unit monomers is complementary to the nucleic acid element portion of at least one of the half-life extension units to form a complementary base pairing structure (e.g., a double-stranded pairing structure); The Drug Unit has a structure according to Formula II: 【Chemistry 3】 The half-life extending drug, characterized in that the half-life extending unit has a structure represented by formula III. 【Chemistry 4】 (In the formula, T is the drug element moiety. A is a half-life extending element moiety. X1 and X2 are each independently none or overlapping peptides. L1 and L2 each independently represent a linker molecule. Y1, Y2 and Z1, Z2 are each independently null or overlapping nucleic acids. W1 and W2 are each independently a nucleic acid sequence selected from the group consisting of an L-nucleic acid, a locked nucleic acid, a thio-modified nucleic acid, a 2'-fluoro-modified nucleic acid, a 5-hydroxymethylcytosine nucleic acid, or a combination thereof. "-" is a conjugated bond. Here, the nucleic acid W1 of the drug unit has at least one complementary pairing region, and the nucleic acid W2 of the half-life extension element has at least one complementary pairing region, and the two are partially or completely complementary.

7. 1. A pharmaceutical composition comprising: (i) a drug having an extended half-life as defined in claim 6 as an active ingredient; (ii) a pharma- ceutically acceptable carrier; A pharmaceutical composition comprising:

Citation Information

Patent Citations

  • Multispecific protein drug and library thereof, preparing method therefor and application thereof

    WO2018205755A1